Phase 1b Study of Ramucirumab in Combination With Fluoropyrimidines and Platinum-Based Agents in Japanese Patients With Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma

Trial Profile

Phase 1b Study of Ramucirumab in Combination With Fluoropyrimidines and Platinum-Based Agents in Japanese Patients With Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma

Completed
Phase of Trial: Phase I

Latest Information Update: 06 Dec 2017

At a glance

  • Drugs Ramucirumab (Primary) ; Capecitabine; Cisplatin; Gimeracil/oteracil/tegafur; Oxaliplatin
  • Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
  • Focus Adverse reactions
  • Sponsors Eli Lilly
  • Most Recent Events

    • 05 Apr 2017 Results assessing safety, tolerability, pharmacokinetics and efficacy, presented at the 108th Annual Meeting of the American Association for Cancer Research
    • 13 Dec 2016 Status changed from active, no longer recruiting to completed.
    • 21 Nov 2016 Planned End Date changed from 1 Dec 2016 to 1 Jan 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top